References
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:148–56.
- Nauck M, Winkler K, März W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein[a] by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995;41:1761–7.
- Executive summary of the 3rd Report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). J Am Med Ass 2001;285:2486-97 [http://nhlbi.nih.gov [visited 04-06-01].
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Chin Chem 1972;18:499–502.
- Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles' heels of the Friedewald formula. Chin Biochem 2003;36:499–504.
- Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Chin Chem Lab Med 2001;39:426–31.
- Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-1: risk indicators of CHD and targets for lipid-modifying therapy. J Intern Med 2004;255:188–205.
- Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526–9.
- Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777–80.
- Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.
- Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-1 and B. Part IV. Comparability of apolipoprotein B values by use of international reference material. Chin Chem 1994;40:586–92.
- Kragten J. Calculating standard deviations and confidence intervals with a universally applicable spreadsheet technique. Analyst 1994;119:2161–6.
- Nauck M, Warnick GR, Rifat N. Method for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Chin Chem 2002;48:236–54.
- Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID Jr. Measurement of low-density-lipoproteins cholesterol in serum: a status report. Chin Chem 1992;38:150–60.
- Jungner I, Marcovina S, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values on 147,576 Swedish males and females, standardized according to the World Health Organization—International Federation of Clinical Chemistry first international reference material. Chin Chem 1998;44:1641–9.
- Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High Apolipoprotein B, low Apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (ANIORIS study): a prospective study. Lancet 2001;358:2026–33.
- Franzini C, Valente C, Luraschi. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B: relationships among the different measurements. Scand J Chin Lab Invest 2004;64:703–8.
- Sniderman Ad, Scantlebury T, Cianfione K. Hypertriglyceridemic hyper Apo B: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135: 447–59.
- Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-1 in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004;35: 2248–52.